Genoa: The European Medicines Agency has opened a new phase in its annual cycle for the Union list of critical medicines, advancing a vulnerability mapping exercise that now sits alongside the political agreement reached on the Critical Medicines Act earlier this month. For hospital pharmacists across the Ligurian coast and beyond, the question stretching into the autumn is whether the refresh will finally translate into fewer phone calls explaining that a familiar antibiotic, oncology infusion or paediatric formulation is unavailable yet again.
The 2026 annual review follows a revised methodology that the Executive Steering Group on Shortages and Safety of Medicinal Products signed off in January and published shortly afterwards. Submissions from national agencies closed at the end of March, and the EMA has used the intervening weeks to weigh evidence on whether substances should be added to the existing roster of more than two hundred molecules or retired because market dynamics have changed. The review covers everything from broad-spectrum antibiotics to neuromuscular blockers used in operating theatres, with criticality assessed against therapeutic value, availability of alternatives and the practical consequences of supply gaps in clinical settings.
Running alongside that exercise is a parallel methodology that the MSSG endorsed in November of last year, focused not on which medicines should be on the list but on where their supply chains are exposed. The framework asks national authorities and industry to look at concentration of active pharmaceutical ingredient producers, fragility in finishing and packaging steps, geographic clustering, and reliance on single transport corridors. A first set of substances drawn from the Union list is being processed through this vulnerability lens, with the aim of feeding actionable findings into regulatory and industrial policy decisions during the second half of the year.
The Critical Medicines Act, on which the institutions reached provisional agreement on twelve May, will give that mapping work legal teeth. Once adopted, it will require manufacturers of products on the Union list to share information needed to assess supply chains and will allow the Commission to support common procurement, encourage diversification of suppliers and accelerate joint stockpiling arrangements between Member States. Officials involved in the talks point out that the act does not on its own conjure new manufacturing capacity, but it does close a structural blind spot in which regulators previously discovered shortages only when prescriptions could not be filled.
Italian regulators, who have been particularly vocal during shortages of paediatric amoxicillin and certain anaesthesia agents, have welcomed the convergence of the list, the vulnerability methodology and the legislative file. The Genoese university hospitals, which run procurement consortia for several neighbouring regions, have already begun adapting their tendering specifications to anticipate the data flows expected from manufacturers under the new framework.
There are still open questions. National competent authorities have queried how the Commission will calibrate solidarity mechanisms when one Member State experiences a sudden gap and others have surplus stock. Industry representatives, for their part, want assurance that vulnerability data will not become a commercial liability if disclosed. EMA officials briefing stakeholders indicate that guidance on data handling will follow the act’s final adoption, alongside templates for the supply chain disclosures.
For patients, the visible change will arrive in stages. The next update to the Union list is due before the summer break, and the first published vulnerability assessments are expected in the autumn. Whether that arc translates into fewer empty pharmacy shelves will depend on how quickly Member States operationalise the new tools, and on whether the cliff edges identified in vulnerability work prompt the kind of industrial response the Commission is hoping to trigger.
